CG Oncology’s bladder cancer treatment shows durability potential in Phase 3

Ayisha Sharma

News Reporter

CG Oncology says its immunotherapy candidate that could help patients avoid surgery may deliver lasting responses in a certain form of bladder cancer based on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

CG Oncology’s bladder cancer treatment shows durability potential in Phase 3

Ayisha Sharma

News Reporter

Sign up to read this article for free.

After CagriSema, eyes are on Lilly’s oral GLP-1 as next key obesity play

Regeneron buys London-based ocular biotech

A look at biotech's year of the megaround

CagriSema’s weight loss data disappointed. What does Novo do next?

Eli Lilly seeks to join lawsuit over end of tirzepatide shortage

Roche circles back to China biotech with $80M deal for lung cancer ADC

CG On­col­o­gy’s blad­der can­cer treat­ment shows dura­bil­i­ty po­ten­tial in Phase 3

Ayisha Sharma

News Reporter

Sign up to read this article for free.

more like this

Af­ter Ca­griSe­ma, eyes are on Lil­ly’s oral GLP-1 as next key obe­si­ty play

Re­gen­eron buys Lon­don-based oc­u­lar biotech

A look at biotech's year of the megaround

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Eli Lil­ly seeks to join law­suit over end of tirzepatide short­age

Roche cir­cles back to Chi­na biotech with $80M deal for lung can­cer ADC

CG Oncology’s bladder cancer treatment shows durability potential in Phase 3

After CagriSema, eyes are on Lilly’s oral GLP-1 as next key obesity play

Regeneron buys London-based ocular biotech

CagriSema’s weight loss data disappointed. What does Novo do next?

Eli Lilly seeks to join lawsuit over end of tirzepatide shortage

Roche circles back to China biotech with $80M deal for lung cancer ADC